@article{d28229b872934b88871810e35c69a30e,
title = "Targeted radioactive therapy for prostate cancer – Authors' reply",
author = "Hofman, {Michael S.} and Shahneen Sandhu and Francis, {Roslyn J.} and Davis, {Ian D.} and Louise Emmett",
note = "Funding Information: MSH reports grants from Movember and Prostate Cancer Foundation of Australia that supported this Correspondence; personal fees from Janssen, Mundipharma, Astellas, Merck Sharp & Dohme, and AstraZeneca, all unrelated to this Correspondence; and research support from Endocyte and Advanced Accelerator Applications (a Novartis Company), unrelated to this Correspondence. SS reports grants from Novartis/AAA, AstraZeneca, Merck Sharp & Dohme, and Genetech; and personal fees from Astra Zeneca, Merck Sharp & Dohme, Bristol Myer Squibb, and AstraZeneca, unrelated to this Correspondence. IDD reports institutional payments to support prostate cancer trials from Pfizer, Bayer, Astellas, Janssen, Movember Foundation, and Merck Sharp & Dohme, all unrelated to this Correspondence. LE reports personal fees from AstraZenca, Janssen, and Astellas, unrelated this Correspondence. RJF declares no competing interests. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = aug,
day = "7",
doi = "10.1016/S0140-6736(21)01060-6",
language = "English",
volume = "398",
pages = "488",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10299",
}
